Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (Baiyunshan Pharmaceutical) has declared a final ordinary dividend of RMB0.45 per share for the financial year ended 31 December 2025, according to a filing published on 20 March 2026.

The proposed distribution is subject to shareholder approval, with the meeting date yet to be disclosed. Key timetable items—including the ex-dividend date, record date, book-closure period and payment date—will be announced in due course.

Shareholders registered on the Hong Kong share register will receive the dividend in Hong Kong dollars; the conversion rate will be communicated once confirmed. Withholding-tax arrangements have not yet been detailed.

Computershare Hong Kong Investor Services Limited remains the appointed share registrar for the distribution process.

The board of directors currently comprises five executive directors and four independent non-executive directors. Baiyunshan Pharmaceutical did not provide any additional information on warrants, convertible securities or supplementary matters in this announcement.